Dutch biotech Argenx is hoping to build a portfolio of autoimmune treatments around Vyvgart, which received FDA approval in 2021 as a treatment for myasthenia gravis. We think the drug will see peak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback